Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roxane Laboratories has announced the approval of its abbreviated new drug application for ropinirole hydrochloride tablets, 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, and 5mg by the FDA.
Subscribe to our email newsletter
The product is available in bottles of 100 and is available for immediate shipment to wholesalers and pharmacies nationwide.
Roxane’s ropinirole hydrochloride tablets are AB rated to Requip tablets and indicated for the treatment of moderate-to-severe primary restless leg syndrome.